Objective: Persons with type 2 diabetes have increased incidence of hyperuricemia and gout. The hypothesis that Urate transporter 1 (URAT1) levels are increased in type 2 diabetic Zucker rats and this is responsible for elevation of uric acid was tested. Methods: Male 12-week-old obese Zucker rats were compared to non-diabetic lean counterparts. Plasma glucose, uric acid and creatinine were measured. URAT1 protein levels in the renal cortex and medulla were determined by Western blot. Immunohistochemistry was used to determine the location of URAT1 in renal tubules. Results: Plasma glucose and uric acid levels were higher in the diabetic rats. There was no difference in plasma createnine. URAT1 antibody-positive bands of 27, 31, 50, 62 and 70 kDa were observed in cortex. A similar pattern was observed in medulla with addition of a 44 kDa band. No differences were observed in URAT1 proteins in the cortex between obese and lean rats. In the medulla, expression of the 44 and 50 kDa proteins was higher in lean rats. Expression of 27, 50, 62 kDa URAT1 proteins in the cortex was higher than in the medulla, while expression of the 70 kDa URAT1 was higher in medulla than in cortex. Localization of URAT1 did not differ between groups and included tubules in both cortex and medulla. Conclusions: In male Zucker rats, URAT1 protein expression was observed in both kidney cortex and medulla. Uric acid elevation in the obese group was associated with decreases in the 44 and 50 kDa URAT1 proteins in renal medulla.
Introduction
Although the body requires certain levels of uric acid (UA) because of its protective antioxidant and iron chelating properties [1, 2] , elevations of systemic UA can lead to gout [3] . Gout is the most common cause of inflammatory arthritis and currently affects 4% of the adult population in the United States (~8.3 million people) [4] . The incidence of gout is much higher in persons with type 2 diabetes mellitus (T2DM) than in non-diabetics [5] . Diabetic nephropathy is associated with elevated serum UA levels [6] , and there is increasing evidence that gout, itself, increases the risk for diabetes, kidney disease, obesity and hypertension [7] . Patients with both gout and T2DM share common genetic factors and there is a mutual interdependent effect on higher incidences [5] . URAT1 (Slc22 A12) and URATv1 (Glut9, Slc2A9) play a major role in UA kidney excretion in humans, rats and mice [8, 9] . URAT1 is found in the renal tubular system and is responsible for the reabsorption of UA [3, 8] . A number of other transporters including OAT 1 (Slc22A6), 3 (Slc22A8), 10 (Slc22A13), and 4 (Slc22A11), NPT1 (Slc17A1), NPT4 (Slc17A3), UAT/galectin9 and uromodulin contribute to urate transport in the kidney [10] [11] [12] [13] . Increased protein levels of URAT1 are observed in mice with obesity/metabolic syndrome [14] , and insulin resistance enhances urate reabsorption by up-regulating URAT1 expression in rats fed a high purine diet [15] . The hypothesis that URAT1 is up-regulated in the kidney in T2DM was tested in the obese Zucker rat (fa/fa) model of T2DM [16] [17] [18] .
Ohio University Institutional Animal Care and Use Committee.
Glucose, Creatinine and Uric Acid Levels
Fasting blood glucose was measured using the One Touch Lifescan glucometer (Johnson and Johnson, New Brunswick, NJ). Plasma UA (QuantiChrom TM Uric Acid Assay Kit, BioAssays Systems, Hayward, CA) and createnine (QuantiChrom TM Creatinine Assay Kit, BioAssays Systems, Hayward, CA) were also quantified.
Western Blot Analysis of URAT1 Levels in Renal Cortex and Medulla
Immunoblots were done to assess URAT1 protein levels in kidney cortex and medulla. The right kidney was separated into cortex and medulla and homogenized in lysis buffer [10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40] containing protease inhibitors. Thirty micrograms of protein was then subjected to SDS-PAGE and Western blotting using the Nu-PAGE System (Invitrogen, Grand Island, NY). Blots were probed with anti-URAT1 (Abbiotec, LCC #250521, San Diego, CA), stripped, and re-probed with anti--actin (Cell Signaling Technology, #4967, Danvers, MA). Signals were visualized and bands quantified using the LI-COR Odyssey Infrared Imaging System (LI-COR, Lincoln, NE). Results are presented as URAT-1/β-actin density ratio.
Immunohistochemistry (IHC)
Following rapid removal, half of the remaining kidney was fixed, embedded and processed as previously described [21] . Sections were incubated overnight at 4˚C with primary rabbit polyclonal URAT1 antibody (3 g/ml, Abbiotec, LCC #250521, San Diego, CA). Isotype controls were performed on a consecutive section using isotype normal rabbit IgG at equivalent concentration to the primary antibody (Invitrogen Corporation, #10500C, Camarillo, CA). Slides were rinsed with PBS and incubated with secondary goat polyclonal anti-rabbit antibody (1:1000 dilution, Abbiotec, LCC #252237, San Diego, CA,) for 1 hour. Immunohistochemical reactivity was detected after reaction with diaminobenzadine (Sigma-Aldrich, St. Louis, MO) and immunostained sections counterstained with hematoxylin.
Evaluation of Immunostaining
IHC-stained slides were examined blindly by light microscopy at 200-fold magnification. URAT1 positive stained tubules in cortex and medulla were counted in 5 randomly selected consecutive fields. In the cortex, proximal and distal immunostained tubules were counted and the proximal/distal tubules ratio calculated. The samples were also evaluated for diffuseness and intensity of staining [22] .
Statistical Analysis
Results were compared between groups using independent samples T-test and paired samples T-test (for comparing results between cortex and medulla within groups) and expressed as the mean ± SEM. The 0.05 level of probability was used as the criterion of significance.
Results

Body and Kidney Weights, and Glucose and UA Levels Are Increased in Obese, Diabetic Zucker Rats
As previously reported, at the age of 12 weeks the obese, diabetic Zucker rats had higher body weights (462.22 ± 6.62 vs. 301.67 ± 11.30 g, p < 0.05) and kidney weights (1.259 ± 0.070 vs. 1.010 ± 0.068 g, p < 0.05) than the lean, non-diabetic counterparts (Figure 1 ) [21] . Obese, diabetic Zucker rats also had higher blood glucose (Figure  2(a) ), but not plasma creatinine (0.446 ± 0.077 vs. 0.631 ± 0.155 mg/dl p > 0.05) than the lean counterparts. Plasma UA levels were elevated in the obese rats (Figure 2(b) ). m of bo factor for and the number one cause of re [23] . In addition, there is an association between elevated serum UA levels, gout, and kidney damage [6] . However, it has been debated over the years 
URAT1 Is Expressed Zucker Rats
Western blot-URAT1 protein is expressed in b x (Figure of obese and lean Zucker rats. Western blot analysis of cortex revealed five URAT1 positive bands at 27, 31, 50, 62 and 70 kDa. A similar banding pattern was observed in Western blots of protein from the medulla. In addition, a 44 kDa band was also detected in medulla. No differences were observed in URAT1 protein levels in the cortex of obese and lean Zucker rats. In medulla, however, the expression of the 44 and 50 kDa proteins was significantly (p < 0.05) higher in lean, non-diabetic Zucker rats. Within groups, the expression of the individual 27, 50, 62 kDa URAT1 bands in cortex was two-fold higher than in medulla. Conversely, expression of the 70 kDa URAT1 band was higher in medulla than in cortex.
Immunohistochemistry-URAT1 positive immunostaining was observed throughout the renal tubular syste th obese, diabetic and lean, non-diabetic Zucker rats (Figure 4) . In kidney cortex, positive staining was observed equally in proximal and distal tubules without differences observed in diffuseness (0.975 ± 0.025 vs. 0.920 ± 0.053 points, p > 0.05), intensity of staining (1.000 ± 0.037 vs. 0.950 ± 0.063 points, p > 0.05) or total IHC scores between diabetic and non-diabetic animals. URAT1 immunostaining was not detected in glomeruli (Figure 4(a) ). In the medulla, the most intensive staining was observed in the inner medulla, associated with the collecting ducts. The same level of URAT1 positive staining was observed in the tubular system of cortex and medulla in both experimental groups.
Discussion
Diabetes is a risk chronic renal failu whether hyperuricemia is a cause or effect of renal dysfunction [24] . The most accepted hypothesis concerning the association between diabetes with gout is that there is a dominantly inherited defect in renal tubular urate handling, causing an imbalance in the reabsorption and secretion of urate by the kidney [25] and subsequent increases in blood UA levels [26] . URAT1 was the first UA transporter identified in the kidney and is thought to be the major mediator of the urate reabsorption pathway and the target of uricosuric drugs [27, 28] . However a large number of additional transporters have been identified and these other reabsorbing (OAT 10, OAT 4 and GLUT9) and secretory (NPY1/NPT4, OAT 1 and OAT 3) transporters may also play a significant role [11] . As reported previously [29, 30] , the obese, male, diabetic Zucker rats have higher blood UA levels than lean, nondiabetic counterparts. Western blots showed the presence of multiple URAT1 positive bands of 27, 31, 50, 62 and 70 kDa in both cortex and medulla and an additional unique 44 kDa band in medulla. Western blot analysis of URAT1 in mice demonstrated both 62 and 70 kDa proteins. The 70 kDa N-glycosylated form is found at the brush border membrane and the native 62 kDa form is located on intracellular organelles [31] . Glycosylation plays critical roles in regulation of intracellular targeting, protein folding, modulation of biological activeity, maintenance of protein stability and formation of recognition structures for interactions with diverse external ligands [32, 33] . Glycosylation is necessary to proper trafficking of the OATs family of proteins which includes transport of URAT1 to the plasma membrane and may enhance substrate recognition. Post-translational phosphorylation may also regulate the activity of transporters [33] [34] [35] , and URAT1 has potential PKA and PKC phosphorylation sites [13] . URAT1 positive immunostaining in Zucker rats was found in proximal and distal renal tubular segents in both cortex and medulla, b m similar to the results reported in male Wistar rats [36] . Interestingly in mice [31] and humans [8] , URAT1 has been described only in cortical tubules. Although Western blots of URAT1 in humans have shown a single 40 kDa protein, functional studies indicate that rat URAT1 mediates reabsorption of UA in a similar manner to human URAT1 and thus it may be possible to extrapolate findings in rats to uncover mechanisms in humans [36] . Based on molecular size, six distinct URAT1 proteins were found in Zucker rat kidney. In addition to posttranscripts which are now known to be characteristic of most genes [ translational modifications, the observed proteins may 37]. Absolute and relative levels of the six transcripts differ between cortex and medulla. There are no increases in any transcript in the diabetic animals. In fact, absolute levels of the 44 and 50 kDa proteins in medulla are decreased in the obese, diabetic rats compared to the lean rats. This may be a response to an increased filtered load of UA in the diabetic animals resulting in decreased secondary reabsorption, as alterations in splicing are known to occur due to internal environmental or epigenetic cues [37, 38] . Alternatively, URAT1 protein levels may not accurately predict transporter activity. Others have shown a decrease in the 60 kDa URAT1 transcript in cortex with exercise and hyperuricemia in rats, associated with elevated URAT1 mediated urate reabsorption [39] . Alternatively spliced transcripts may also have non-coding regulatory functions [40] . It is also possible that URAT1 or a closely related protein is involved in the transport of other anions in the rat medulla [11, 12] .
Conclusion
In male Zucker rats, URAT1 protein expression was observed in both kidney cortex and medulla. Uric acid elevation in the obese group w 
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